Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

LABP

Landos Biopharma (LABP)

Landos Biopharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LABP
DateHeureSourceTitreSymboleSociété
03/06/202412h04Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:LABPLandos Biopharma Inc
23/05/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
23/05/202422h52Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:LABPLandos Biopharma Inc
23/05/202422h49Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:LABPLandos Biopharma Inc
23/05/202422h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
23/05/202422h05PR Newswire (US)AbbVie Completes Acquisition of Landos BiopharmaNASDAQ:LABPLandos Biopharma Inc
09/05/202414h32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LABPLandos Biopharma Inc
25/03/202413h31PR Newswire (US)AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNASDAQ:LABPLandos Biopharma Inc
14/02/202422h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LABPLandos Biopharma Inc
01/06/202322h20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:LABPLandos Biopharma Inc
25/05/202322h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LABPLandos Biopharma Inc
24/05/202323h58Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LABPLandos Biopharma Inc
12/05/202314h48Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LABPLandos Biopharma Inc
19/04/202314h06Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LABPLandos Biopharma Inc
19/04/202314h01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LABPLandos Biopharma Inc
30/03/202323h28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LABPLandos Biopharma Inc
23/03/202313h58Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:LABPLandos Biopharma Inc
23/03/202313h31Edgar (US Regulatory)Annual Report (10-k)NASDAQ:LABPLandos Biopharma Inc
28/02/202323h00GlobeNewswire Inc.Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ FounderNASDAQ:LABPLandos Biopharma Inc
14/02/202323h26Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:LABPLandos Biopharma Inc
11/01/202313h00GlobeNewswire Inc.Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis OrganizationNASDAQ:LABPLandos Biopharma Inc
05/01/202313h05GlobeNewswire Inc.Landos Biopharma Provides Comprehensive Update on Clinical Development PlansNASDAQ:LABPLandos Biopharma Inc
05/01/202313h00GlobeNewswire Inc.Landos Biopharma Announces $16.7 Million Private Placement FinancingNASDAQ:LABPLandos Biopharma Inc
14/11/202204h56TipRanksSVB Securities Sticks to Its Hold Rating for Landos Biopharma (LABP)NASDAQ:LABPLandos Biopharma Inc
11/11/202200h05TipRanksLandos Biopharma (LABP) Receives a Hold from JonesTradingNASDAQ:LABPLandos Biopharma Inc
10/11/202214h00GlobeNewswire Inc.Landos Biopharma Reports Third Quarter 2022 Results and Provides Business UpdateNASDAQ:LABPLandos Biopharma Inc
06/09/202213h00GlobeNewswire Inc.Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical OfficerNASDAQ:LABPLandos Biopharma Inc
16/08/202212h08Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LABPLandos Biopharma Inc
12/08/202214h36TipRanksSVB Securities Keeps Their Hold Rating on Landos Biopharma (LABP)NASDAQ:LABPLandos Biopharma Inc
11/08/202214h30GlobeNewswire Inc.Landos Biopharma Reports Second Quarter 2022 Results and Provides Business UpdateNASDAQ:LABPLandos Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:LABP

Dernières Valeurs Consultées

Delayed Upgrade Clock